Abstract:Key PointsMuscle wasting is a debilitating condition that develops with ageing and more rapidly with inactivity (bed rest) and in various systemic diseases (for example, cancer, renal failure, chronic obstructive pulmonary disease, sepsis, HIV and trauma). Fibre atrophy primarily results from an acceleration of protein degradation, often combined with reduced protein synthesis. Treatments that prevent this activation of proteolysis or increase protein synthesis offer considerable promise to combat this debilitating process.Various types of rapid muscle wasting develop through a common transcriptional programme involving the induction of a set of atrophy-related genes (atrogenes) by forkhead box protein O (FOXO) transcription factors and reduced signalling by the PI3K–AKT–mTOR pathway.The resulting muscle weakness is a consequence of the degradation of myofibrils, which is catalysed by ubiquitin ligases that target different components of the contractile apparatus for proteasomal degradation. By contrast, the loss of endurance results from the breakdown of mitochondria via autophagy.Myostatin, an autocrine inhibitor of normal muscle growth, and its circulating homologue activin A, also trigger muscle protein loss in various catabolic states via the activation of SMAD2 and SMAD3, which function together with FOXO transcription factors.Antibodies against myostatin or activin A, or agents that block their receptor — activin A receptor, type IIB (ActRIIB) — in muscle could be a promising approach to combat muscle loss caused by cancer-associated cachexia, renal failure and ageing. Indeed, these treatments helped to preserve muscle and prolong longevity in tumour-bearing mice, and several of these treatments are currently in clinical trials.Glucocorticoids and various circulating inflammatory mediators, such as tumour necrosis factor-α (TNFα) and interleukin-6 (IL-6), have also been implicated in excessive muscle proteolysis in cachexia, but their roles in different catabolic states remain uncertain and controversial.Recent studies have increased our understanding of the biochemical mechanisms of atrophy and have identified many intracellular proteins that are crucial in muscle wasting (for example, SMADs, tripartate motif-containing protein 32 (TRIM32), nuclear factor-κB (NF-κB)) or that combat this process (for example, peroxisome proliferator-activated receptor-γ coactivator 1α (PGC1α), sirtuin1 (SIRT1) and JUNB). Their manipulation by small molecules offers many opportunities for the rational design of new treatments for this condition.

The ubiquitin proteasome system in atrophying skeletal muscle: roles and regulation

Ubiquitin-Proteasome Pathway and Muscle Atrophy

The ubiquitin–proteasome system in regulation of the skeletal muscle homeostasis and atrophy: from basic science to disorders

Ubiquitin-proteasome pathway in skeletal muscle atrophy

The dependency of autophagy and ubiquitin proteasome system during skeletal muscle atrophy

Muscle wasting in disease: molecular mechanisms and promising therapies

Cellular and molecular mechanisms of muscle atrophy

Deubiquitinases in muscle physiology and disorders

Out of Control: The Role of the Ubiquitin Proteasome System in Skeletal Muscle during Inflammation

Dual Roles of Mtorc1-Dependent Activation of the Ubiquitin-Proteasome System in Muscle Proteostasis

Skeletal muscle atrophy: From mechanisms to treatments

The role of TGF-β signaling in muscle atrophy, sarcopenia and cancer cachexia

ER stress in skeletal muscle remodeling and myopathies

Muscle wasting from kidney failure-a model for catabolic conditions

Role and Regulation of Autophagy in Mass Maintenance of Skeletal Muscle

Emerging Strategies Targeting Catabolic Muscle Stress Relief

Atrogin-1 promotes muscle homeostasis by regulating levels of endoplasmic reticulum chaperone BiP

Integrated Genomic and Proteomic Analyses Identify Stimulus-Dependent Molecular Changes Associated with Distinct Modes of Skeletal Muscle Atrophy

Skeletal muscle atrophy: Potential therapeutic agents and their mechanisms of action

Antagonistic control of myofiber size and muscle protein quality control by the ubiquitin ligase UBR4 during aging

Skeletal muscle wasting in cachexia and sarcopenia: molecular pathophysiology and impact of exercise training